a study of different sequences of cilta-cel, talquetamab in combination with daratumumab and teclistamab in combination with daratumumab following induction with daratumumab, bortezomib, lenalidomide and dexamethasone in participants with standard-risk newly diagnosed multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. this is defined as a composite of sustained (at least 2 years) minimal residual disease (mrd) negativity with complete response/stringent complete response (cr/scr) and a positron emission tomography/computed tomography (pet/ct) scan that does not show any signs of cancer at 5 years. mrd negativity and cr/scr is defined as no detectable signs of remaining cancer cells after the treatment. this study will also characterize how well the treatments administered work in the study through progression-free survival (pfs). pfs is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.


Eligibility criteria:
inclusion criteria: * participants with documented new diagnosis of multiple myeloma (mm) according to international myeloma working group (imwg) diagnostic criteria and with no prior myeloma-directed therapy * participants must have standard-risk mm (stage i and ii) based on revised international staging system (r-iss) * participants must be considered fit (score equals to \[=\] 0) or intermediate-fit (score=1) according to imwg frailty index assessment (based on the charlson comorbidity index, the katz activity of daily living and the lawson instrumental activities of daily living) * measurable disease defined as: serum monoclonal paraprotein (m-protein) level greater than or equal to (\>=) 1.0 gram per deciliter (g/dl) (\>=10 gram per liter \[g/l\] for institutions using alternative units) or urine m-protein level \>= 200 milligrams per 24 hours (mg/24 hours); light chain mm without measurable disease in the serum or the urine: serum immunoglobulin free light chain \>=10 milligrams per deciliter (mg/dl) (\>=100 mg/l for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio * eastern cooperative oncology group (ecog) performance status grade of 0 or 1 exclusion criteria: * any ongoing myelodysplastic syndrome or b-cell malignancy (other than mm). any history of malignancy, other than mm, which is considered at high risk of recurrence requiring systemic therapy * peripheral neuropathy or neuropathic pain of grade \>= 2, as defined by national cancer institute (nci)-common terminology criteria for adverse events (ctcae) version 5.0 * known active or prior history of central nervous system (cns) involvement or exhibits clinical signs of meningeal involvement of mm * stroke or seizure within 6 months of signing the informed consent form (icf) * plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (\>= 5 percent \[%\] circulating plasma cells in peripheral blood smears), waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(poems) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction * presence of high-risk disease features: (a) cytogenetic high risk lesions by mm fluorescence in situ hybridization (fish) including deletion 17p (del\[17p\])/, t(4;14), t(14;16), amplification 1q (amp\[1q21\]) (\>= 4 copies); (b) presence of 1 or more extramedullary plasmacytomas * seropositive for human immunodeficiency virus (hiv)